Cantor Fitzgerald Weighs in on AxoGen FY2024 Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Stock analysts at Cantor Fitzgerald cut their FY2024 earnings per share estimates for shares of AxoGen in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now expects that the medical equipment provider will post earnings of ($0.58) per share for the year, down from their previous estimate of ($0.28). The consensus estimate for AxoGen’s current full-year earnings is ($0.30) per share. Cantor Fitzgerald also issued estimates for AxoGen’s FY2025 earnings at $0.19 EPS.

Separately, StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th.

AxoGen Price Performance

AxoGen stock opened at $18.70 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a market cap of $822.99 million, a P/E ratio of -58.44 and a beta of 1.01. The business’s fifty day moving average is $15.53 and its two-hundred day moving average is $13.34. AxoGen has a 52 week low of $5.55 and a 52 week high of $19.06.

Institutional Investors Weigh In On AxoGen

A number of institutional investors and hedge funds have recently made changes to their positions in AXGN. Rhumbline Advisers raised its position in shares of AxoGen by 6.2% during the second quarter. Rhumbline Advisers now owns 58,157 shares of the medical equipment provider’s stock worth $421,000 after acquiring an additional 3,380 shares during the last quarter. Squarepoint Ops LLC raised its position in shares of AxoGen by 186.1% during the second quarter. Squarepoint Ops LLC now owns 60,913 shares of the medical equipment provider’s stock worth $441,000 after acquiring an additional 39,624 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of AxoGen during the third quarter worth $227,000. Creative Planning raised its position in shares of AxoGen by 152.2% during the third quarter. Creative Planning now owns 29,790 shares of the medical equipment provider’s stock worth $418,000 after acquiring an additional 17,980 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in AxoGen in the third quarter valued at about $56,000. Institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.